Fecal microbiota transplantation for recurrent Clostridioides difficile infection in frail and very old patients

Abstract

BackgroundOlder age is a well‐known risk factor for recurrent and severe Clostridioides difficile infection (CDI). Fecal microbiota transplantation (FMT) is widely recognized as an effective and safe therapeutic option for the treatment of recurrent CDI (rCDI). However, the efficacy and safety of FMT for rCDI in very old patients are uncertain. This study evaluated the efficacy and safety of FMT in a group of very old subjects with rCDI, and the reliability of overall comorbidity and frailty assessment for identifying patients at higher risk of worse clinical outcomes.MethodsThis is a retrospective single‐center study including patients ≥85 years undergoing FMT for rCDI between 2014 and 2022. Primary outcomes included efficacy of FMT, defined as cure of CDI at 8 week‐follow‐up, and safety evaluation. At baseline, comorbidity was measured with the Charlson Comorbidity Index (CCI). Frailty was measured with the Clinical Frailty Scale (CFS).ResultsOverall, 43 patients with a median age of 88 years underwent FMT by colonoscopy in the study period. The rate of first FMT success was 77%. Five of the 10 patients who failed the first FMT infusion were cured after repeat FMT, with an overall efficacy of 88%. In patients with successful treatment, the CFS was significantly lower compared to those who failed the FMT or underwent repeat FMT (p < 0.01 for both). Mild adverse events occurred in 11 patients (25%). One death, not related to FMT or rCDI, occurred within 7 days from the first procedure.ConclusionsFMT is effective and safe in very old patients. Frailty and high comorbidity do not limit use of FMT in these patients. Frailty assessment has potential to better identify patients at higher risk of worse outcomes or for repeat treatment with FMT.

Main Disorders of Gastrointestinal Tract in Older People: An Overview

“…In recent years, fecal microbiota transplantation (FMT) has emerged as a highly effective treatment of severe, fulminant, recurrent, or refractory forms of CDI, with high efficacy and an overall high safety level. The cumulative experience from case series and controlled trials shows that FMT is effective (80-90%) and safe when used to treat relapsing CDI, also in frail and very old patients [116,117].…”